Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Phase 3

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Atezolizumab
Drug: Cabozantinib

First Posted Date: 2020-04-08

Last Posted Date: 2025-04-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 522

Registration Number: NCT04338269

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇫🇷
CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre, Bordeaux, France
🇫🇷
Centre Francois Baclesse, Caen, France

and more 122 locations

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Phase 1

Completed

Conditions: Biliary Tract Cancer
Secondary Liver Cancer
Liver Metastases
Carcinoma, Hepatocellular

Interventions: Drug: RO7119929
Drug: Tocilizumab

First Posted Date: 2020-04-08

Last Posted Date: 2024-12-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 55

Registration Number: NCT04338685

Locations: 🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇭🇰
Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong

and more 7 locations

A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Thymic

Interventions: Drug: Atezolizumab

First Posted Date: 2020-03-25

Last Posted Date: 2024-06-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 34

Registration Number: NCT04321330

Locations: 🇨🇳
West China Hospital, Sichuan University; Department of Breast, Chengdu, China
🇨🇳
Sichuan Cancer Hospital, Chengdu City, China
🇨🇳
The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China

and more 7 locations

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

Phase 3

Completed

Conditions: COVID-19 Pneumonia

Interventions: Drug: Tocilizumab (TCZ)
Drug: Placebo

First Posted Date: 2020-03-25

Last Posted Date: 2021-06-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 452

Registration Number: NCT04320615

Locations: 🇺🇸
Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States
🇺🇸
Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States
🇨🇦
University Health Network, Toronto, Ontario, Canada

and more 59 locations

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Phase 1

Completed

Conditions: B-cell Lymphoma

Interventions: Drug: Gemcitabine
Drug: Glofitamab
Drug: Oxaliplatin
Drug: Mosunetuzumab
Drug: Obinutuzumab
Drug: Tocilizumab

First Posted Date: 2020-03-18

Last Posted Date: 2024-03-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 23

Registration Number: NCT04313608

Locations: 🇦🇺
Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia
🇦🇺
Monash Health Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia

A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Carcinoma, Small Cell Lung

Interventions: Drug: Atezolizumab
Other: Placebo
Drug: Tiragolumab

First Posted Date: 2020-03-16

Last Posted Date: 2023-10-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT04308785

Locations: 🇨🇳
Anhui Province Cancer Hospital, Hefei City, China
🇨🇳
Guangxi Cancer Hospital of Guangxi Medical University, Nanning, China
🇨🇳
Tianjin Cancer Hospital, Tianjin, China

and more 14 locations

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Drug: Eciskafusp Alfa
Drug: Atezolizumab

First Posted Date: 2020-03-11

Last Posted Date: 2025-05-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 189

Registration Number: NCT04303858

Locations: 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇩🇰
Herlev Hospital, Herlev, Denmark
🇪🇸
Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain

and more 9 locations

A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

Interventions: Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2020-03-09

Last Posted Date: 2025-03-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 172

Registration Number: NCT04300647

Locations: 🇮🇹
Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy
🇵🇦
Centro Oncológico de Panamá, Panama, Panama
🇵🇦
The Panama Clinic, Panama, Panama

and more 53 locations

A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

Phase 2

Completed

Conditions: Autism Spectrum Disorder (ASD)

Interventions: Drug: Placebo
Drug: RO7017773

First Posted Date: 2020-03-06

Last Posted Date: 2025-01-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 104

Registration Number: NCT04299464

Locations: 🇮🇹
Ist. G. Gaslini, Genova, Liguria, Italy
🇮🇹
Istituto Scientifico Medea, Bosisio Parini (LC), Lombardia, Italy
🇮🇹
P.O. Gaspare Rodolico, Catania, Sicilia, Italy

and more 18 locations

A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Venetoclax
Drug: Trastuzumab emtansine

First Posted Date: 2020-03-06

Last Posted Date: 2021-11-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1

Registration Number: NCT04298918

Locations: 🇦🇺
Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy